Mitochondria Are Aging Clocks Through Signaling, Not Just Energy Failure
New review argues aging stems from disrupted mitochondrial signaling, not ATP loss—and mild complex I inhibition may extend healthspan.
Summary
A 2025 review in Genes & Development challenges the long-held view that mitochondria drive aging by losing ATP production or accumulating DNA mutations. Instead, Budinger and Chandel argue that mitochondria function as critical signaling organelles, and it is the disruption of these signals—not energy failure—that drives physiologic aging. Evidence from C. elegans, Drosophila, and mice shows that mild inhibition of mitochondrial respiration can actually extend healthspan. Metformin, which mildly inhibits complex I, exemplifies this paradox: it lowers blood sugar, reduces cancer risk, prevents thrombosis from air pollution, and may suppress clonal hematopoiesis—all through mitochondrial signaling modulation rather than energy deprivation.
Detailed Summary
For decades, mitochondrial dysfunction was understood through the lens of energy failure and oxidative damage. The 'free radical theory of aging,' dating to Harman's 1956 hypothesis, proposed that ROS produced during respiration damage mitochondrial DNA, creating a vicious cycle of worsening dysfunction that limits lifespan. This review argues that this framework is outdated and unsupported by modern evidence.
The authors point out that mtDNA mutations do accumulate with age, but not at levels sufficient to impair ATP or anabolic output meaningfully. In POLG mutator mice, heterozygotes accumulate over 30-fold more mtDNA mutations than aged wild-type animals yet show normal lifespan and healthspan—only homozygotes with extreme mutation burdens show premature aging phenotypes. Similarly, reducing expression of complex I subunits by 50% in mice causes no detectable age-related phenotype.
Critically, the review reframes mitochondria as signaling hubs. They release ROS, mtDNA, mtRNA, and metabolites into the cytosol to regulate inflammation, epigenetics, stress responses, and cell death. Age-related structural changes—like altered cristae organization—can disrupt these signals without impairing oxidative phosphorylation. In C. elegans, inhibiting neuronal respiration triggers systemic longevity responses via secreted mitokines, demonstrating non-cell-autonomous mitochondrial signaling in aging.
The therapeutic implications center on metformin and POLRMT inhibitors (IMTs). Using the yeast enzyme NDI1—which replaces complex I function but does not bind metformin—the authors' own lab confirmed that complex I is metformin's primary in vivo target. Metformin's wide-ranging benefits (antidiabetic, anticancer, anti-thrombotic, and potential suppression of clonal hematopoiesis) are all mechanistically linked to mild, reversible complex I inhibition that rebalances mitochondrial signaling. IMT compounds similarly reversed diet-induced hepatosteatosis and insulin resistance in mice through liver-specific mitochondrial transcription inhibition without systemic toxicity.
The central thesis—that optimal mitochondrial signaling, neither too active nor too suppressed, is key to healthspan—opens the door to pharmacologic strategies that fine-tune rather than eliminate mitochondrial function. This represents a paradigm shift with significant implications for aging medicine.
Key Findings
- mtDNA mutation rates during normal aging are insufficient to impair ATP production or drive aging phenotypes in mice.
- Mild mitochondrial respiration inhibition in C. elegans and Drosophila extends lifespan via systemic stress-resilience signaling.
- Metformin's healthspan benefits are mechanistically linked to mild complex I inhibition, confirmed using yeast NDI1 replacement experiments.
- POLRMT inhibitors (IMTs) reversed obesity and hepatic steatosis in mice with liver-specific mitochondrial targeting and no systemic toxicity.
- Metformin suppresses clonal hematopoiesis in mice and is associated with lower clonal hematopoiesis prevalence in UK Biobank human data.
Methodology
This is a narrative review synthesizing findings from genetic model organisms (C. elegans, Drosophila, mice), mouse genetic engineering (POLG mutators, NDI1 expression, NDUFS2 heterozygotes), pharmacologic studies (metformin, IMTs), and human epidemiologic data (UK Biobank). No original experiments are reported; evidence is drawn from published literature by the authors and others.
Study Limitations
As a short review/outlook piece, this paper presents no new primary data and relies on synthesized evidence that varies in strength across model organisms and humans. Causal evidence in humans remains limited, and the precise mechanisms by which disrupted mitochondrial signaling drives each aging phenotype are not fully established. Translation of findings from C. elegans and mice to human aging biology requires caution.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.